refractory CD22-positive B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
refractory CD22-positive B-cell Precursor Acute Lymphoblastic Leukemia (ALL) is the indication for 1 drug in DrugBank. It is covered by 2 curated, structured indications.
- Classified under
- Indicated drugs
What you can answer from here — as of October 22, 2026
1Indicated drugWith each drug's targets and mechanismListed above
2Structured indicationsPopulation, line of therapy, route and combination as fields, not proseSign in
Which approved drugs for refractory CD22-positive B-cell Precursor Acute Lymphoblastic Leukemia (ALL) share a target, and which companies have late-stage candidates against it?
Create a free account or log in to explore the full data card.
Create Account